🇺🇸 Angiomax (bivalirudin) in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 21

Most-reported reactions

1. Thrombosis In Device — 5 reports (23.81%)
2. Myocardial Infarction — 3 reports (14.29%)
3. Acute Respiratory Distress Syndrome — 2 reports (9.52%)
4. Atelectasis — 2 reports (9.52%)
5. Coronary Artery Thrombosis — 2 reports (9.52%)
6. Electrocardiogram St Segment Elevation — 2 reports (9.52%)
7. Post Procedural Complication — 2 reports (9.52%)
8. Anxiety — 1 report (4.76%)
9. Blood Glucose Increased — 1 report (4.76%)
10. Blood Potassium Decreased — 1 report (4.76%)

Source database →

Frequently asked questions

Is Angiomax (bivalirudin) approved in United States?

Angiomax (bivalirudin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Angiomax (bivalirudin) in United States?

The Medicines Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.